Topics

Revenues From New Drugs – And Thoughts on Chance

09:06 EDT 12 Jul 2019 | Science

Here’s an interesting analysis of the industry from IDEA Pharma, via Endpoints. They’re looking at the revenues from the more recent drugs in the pipeline (approved in the last five years) and comparing that to each company’s total R&D spending. The list is all Big Pharma – the cutoff is companies that have at least

Original Article: Revenues From New Drugs – And Thoughts on Chance

NEXT ARTICLE

More From BioPortfolio on "Revenues From New Drugs – And Thoughts on Chance"

Quick Search